FAR AWAY FROM HERD IMMUNITY TO SARS-CoV-2: results from a

1

2 survey in healthy blood donors in South Eastern Italy 3 4 Josè Ramòn Fiore1, Michele Centra2, Armando De Carlo3*, Tommaso Granato2, Annamaria 5 Rosa3*, Michelina Sarno2, Lucia De Feo2, Mariantonietta Di Stefano1, Maria L. D'Errico1, 6 Sergio Lo Caputo1, Rosella De Nittis4, Fabio Arena4, Gaetano Corso5, Maurizio 7 Margaglione6 Teresa Antonia Santantonio1 8 9 1) Department of Clinical and Experimental Medicine, Section of Infectious Diseases, University of 10 Foggia, School of Medicine, Foggia, Italy 11 2) Transfusion Medicine Center, Ospedali Riuniti University Hospital, Foggia, Italy 12 3) Laboratory analysis, Ospedali Riuniti University Hospital, Foggia, Italy 13 4) Department of Clinical and Experimental Medicine, Section of Microbiology, University of Foggia, 14 School of Medicine, Foggia, Italy 15 5) Department of Clinical and Experimental Medicine, Section of Clinical Biochemistry, University of 16 Foggia, School of Medicine, Foggia, Italy 17 6) Department of Clinical and Experimental Medicine, Section of Genetics, University of Foggia, 18 School of Medicine, Foggia, Italy 19 20 **Corresponding Author** 21 Jose Ramon Fiore MD, PhD 22 Department of Clinical and Experimental Medicine 23 Section of Infectious Diseases, University of Foggia 24 Ospedali Riuniti University Hospital 25 Via Luigi Pinto 1 71100 Foggia (Italy) Email jose.fiore@unifg.it 26

29

ABSTRACT 28 Here we present results from a survey on anti-SARS-CoV-2 seroprevalence in healthy blood donors 30 from a low incidence COVID-19 area (Apulia region, South Eastern Italy). 31 Among 904 subjects tested, only in 9 cases (0.99%) antibodies against SARS-CoV-2 were 32 demonstrated. All the 9 seropositive patients were negative for the research of viral RNA by RT-33 PCR in nasopharyngeal swab. 34 These data, along with those recently reported from other countries, clearly show that we are very 35 far from herd immunity and that the containment measures are at the moment the only realistic 36 instrument we have to slow the spread of the pandemic. 37 38

INTRODUCTION

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

Herd immunity is a concept in epidemiology that describes how people can collectively stave off infections if some percentage of the population has immunity to it. When most of a population is immune to an infectious disease, this provides indirect protection, or herd protection, to those who are not immune (1) There are two ways to achieve herd immunity: a large proportion of the population either gets infected or gets a protective vaccine. Based on early estimates of SARS-CoV-2 infectiousness, it should be likely needed at least 60-70% of the population to be immune to have herd protection (2). However, more recently mathematical models suggest that lower thresholds could be enough to place populations over the herd immunity threshold once as few as 43% (3) or even 10-20% of its individuals are immune. (4) It is therefore important and urgent to evaluate the extent of circulation (and thus of immunity to) Of SARS-CoV-2 in the general populations of affected countries because this information should guide the extent of reduction or increasing of preventive measures such as social distancing etc. Italy registered the first imported cases of infection in January 31 2020 and after one week the first local case. After that, a dramatic burden of infections was diagnosed: 235.278 cases (with 33.964 deaths) as for June 8 2020, with main clusters in Northern Italy. As a whole, 390 infections/100.000 inhabitants. In Foggia (Apulia region, South Eastern Italy) the first case was observed in March the 1st and as for **June 8**, 1162 cases were diagnosed with an incidence of 187 cases/100.000 inhabitants (5)). Although the total number of diagnosed infections is moderate, we miss clear information regarding the number of individuals in the general population that became immune, possibly acquiring the virus with no or mild symptoms.

Studies on blood donor cohorts are useful to evaluate the prevalence, incidence and natural course of infectious diseases in the general population and may thus help to assess both the viral circulation and the evolution of the COVID-19 outbreak.

We therefore studied a group of healthy blood donors from Foggia province for the presence of IgM and IgG to antibodies to SARS-CoV-2 to examine the circulation of the virus in the general population three months after the local start of the epidemic.

SUBJECTS, MATERIAL AND METHODS

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

SUBJECTS The main study cohort was composed of blood donors, who were apparently healthy subjects, aged 18-65 years. Exclusion criteria were active infection or medical conditions, recent surgical procedures, stay in endemic areas, reported risk factors for parenterally acquired infections, chronic degenerative conditions, diagnosis of cancer or high risk of cardiovascular events. All donors underwent clinical examination, medical history evaluation and biochemical testing. All subjects should had been free of recent symptoms possibly related to COVID-19, nor had close contact with confirmed cases, symptoms free during the preceding 14 days, nor had contacts with suspected cases. Each blood donor signed written informed consents allowing for testing for communicable diseases, storing anonymized data and biological materials for diagnostic/research purposes, and use of their anonymous data for clinical research. A total of 904 blood donors, referring to the Transfusional Center at the "Ospedali Riuniti" University Hospital (Foggia, Italy) were included in the study and subjected to the search for anti-SARS-CoV-2 antibodies, in the period May1-31 2020. In the case of positivity, subjects were recalled and RT-PCR for detection SARS-CoV-2 from nasopharyngeal swabs was performed.

METHODS

89

90

91 **Detection of anti SARS Cov 2 antibodies** 92 Anti-SARS-CoV-2 IgG and IgM were analyzed by using a chemiluminescent analytical assay 93 (CLIA) commercially available kit (New Industries Biomedical Engineering Co., Ltd [Snibe], 94 Shenzhen, China) performed according to the manufacturers instructions. Reagent wells were 95 coated with recombinant structural protein CoV-S (spike) and e CoV-N (nucleocapside) of SARS-96 CoV-2 for both IgM and IgG assay. For IgM assay, the microspheres were coated with a 97 monoclonal antibody to capture human IgM followed by the addition of recombinant antigen from 98 virus 2019-nCoV marked with amino-butyl-ethyl-isoluminol (ABEI). The samples, serum or 99 plasma, were diluted by instrument. The relative light units (RLU) detected is proportional to the 100 concentration of IgG/M in sample. An RLU-ratio of the measurement of each sample to the 101 supplied calibrator was calculated. According to manufacturer instructions for the IgG assay 102 arbitrary units of <1 was considered negative, 1.0 to 1.1 borderline and >1.1 positive; for IgM, an 103 AU/mL < 0.9 was considered negative, 0.9 to 1.0 borderline and > 1.0 positive. 104 Manufacturers claimed that the calculated clinical sensitivities of IgM and IgG were 78.65% and 105 91.21%, respectively, while specificities of IgM and IgG were 97.50% and 97.3%, respectively. 106 107 RT-PCR for detection SARS-CoV-2 from nasopharyngeal swabs 108 Viral RNA was extracted within 2 hours from sample collection using the STARMag 96 X 4 109 Universal Cartridge kit with the Microlab NIMBUS IVD instrument according to the 110 manufacturer's instructions (Seegene Inc. Seoul, Korea). Amplification and detection of target 111 genes (N, E and RdRP) was performed using the commercially available kit AllplexTM 2019-nCoV 112 Assay (Seegene Inc. Seoul, Korea) with the CFX96TM instrument (Bio-Rad, Hercules, CA). 113 Results interpretation was performed with the Seegene Viewer software.

A total of 904 subjects were enrolled in this study (666 males and 239 females) ranging from 18 to 65 years (Table 1). Among them, 9 tested positive for antibodies to SARS-CoV-2: in 8 cases only IgG antibodies were found while in 1 case both IgG and IgM were detected, with a percentage of positivity in the blood donor population of 0.99 %.

No statistical differences were observed in the rate of antibody detection according to the sex and the age.

None of these subjects had clinical signs or symptoms and laboratory parameters alterations; all of them tested negative for RT-PCR research of SARS-CoV-2 RNA in two nasopharyngeal swabs performed on two consecutive days.

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

DISCUSSION

Herd immunity is the resistance to the spread of a contagious disease that results if a sufficient proportion of a population is immune due to natural infection or mass vaccination. Because an effective COVID-19 vaccine is not yet available, herd immunity can be established if a large proportion of immune persons exist in a population to confer indirect protection from infection to susceptible individuals. The breadth of the barrier required to achieve herd immunity depends in large part on viral spread and infectivity. In the nomenclature of epidemiology, the basic reproduction number or R0 and the classical formula for calculating a herd immunity threshold is 1—1/R0. The higher the R0, the higher the threshold required for achieving herd immunity. Other important factors in calculating herd immunity thresholds include the number of social interactions and their durations, innate differences in individual immune responses, and divergent exposures to the infectious microbe (1) People who recover from a COVID-19 coronavirus infection, at least for some time, develop immunity to the virus (6). The disease-induced herd immunity threshold for SARS-CoV-2, according to various epidemiologists, is believed to be around 60 to 70 percent (2) More recently, some researchers have reported lower thresholds: from 43% to just 10 to 20% of the population (3, 4), suggesting that we could reach herd immunity thresholds by natural infections in the setting of COVID-19 pandemic. Recently, data from Spain, France and Italy (7-9) countries that adopted strict lockdown measures indicate a very low seroprevalence in the general population (4.4%, 5% and 7.1%, respectively). Noteworthy, even in Sweden, a country that decided for a herd immunity strategy, with very light restrictions on daily life, antibodies to SARS-CoV-2 were detectable in only 7.5% of the general population in Stockholm (10).

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170171

172

173

174

175

176

In other geographical regions, serosurveys in healthy individuals demonstrated a very low rate of positivity for SARS-CoV-2 (11-15). In our study, we confirm a low rate of antibodies against SARS-CoV-2 on a group of blood donors from a geographical region with a moderate incidence (187 cases/100.000 inhabitants vs the national data of 390 infections/100.000 inhabitants). A limitation of our study is that the enrolled population (18-65 years old) is representative of only a part of the general population, since in Italy 22% of the individuals is aged >65 years (16) However, presented data are relevant in that they refer to the more acting/interacting group of the population, also important from a productive point of view. Certainly, we are far away from herd immunity and even from the more optimistic projections of threshold (10 to 20% of the population) to adopt more relaxed strategies. In conclusion, strengthening herd immunity to control the COVID-19 epidemic is not a viable option as large numbers of people are expected to become infected and many may die from COVID-19. Preventive measures, including physical distancing, remain essential to contain the spread of infection until herd immunity can be safely acquired with the vaccine. Health authorities should take in account these considerations when facing the public health measures to be adopted throughout the COVID-19 transition phases.

177 1) Metcalf C.J.E, Ferrari M., Graham A.L., Grenfell B.T. Understanding Herd 178 Immunity. Trends Immunol. 2015;36(12):753-755. 179 2) Randolph H.E., Barreiro L.B. Herd Immunity: Understanding COVID-19. Immunity. 180 181 $2020;52(5):737 \square 741.$ 182 183 3) Britton T., Trapman P., Ball F.G. The disease-induced herd immunity level for Covid-19 is 184 substantially lower than the classical herd immunity level. 185 medRxiv 2020.05.06.20093336; doi: https://doi.org/10.1101/2020.05.06.20093336 186 187 4) Gabriela M., Gomes M., Corder R. M., King, J. G., Langwig K. E., Souto-Maior, C. et al, 188 Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity 189 threshold. medRxiv 2020.04.27.20081893. https://doi.org/10.1101/2020.04.27.20081893 190 191 5) http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?li 192 ngua=italiano&menu=notizie&p=dalministero&id=4870 193 194 6) Braun J., Loyal L., Frentsch M., Wendisch D., Georg P., Kurth F. et al. Presence of SARS-195 CoV-2 T cells reactive in COVID-19 patients healthy donors. and 196 MedRxiv 2020.04.17.20061440; doi: https://doi.org/10.1101/2020.04.17.20061440 197 198 7) Ministerio de Sanidad, Consumo y Bienestar Social Estudio Ene COVID 19: Primera ronda 199 estudio nacional de sero-epidemiologia de la infeccion por SARS-COV-2 en Espana. 200 Informe preliminar 13 de 2020 Mayo de 201 https://www.mscbs.gob.es/gabinetePrensa/notaPrensa/pdf/ENE-C140520115618104.pdf

202

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

8) Salje H., Tran Kiem C., Lefrancq N., Courtejoie N., Bosetti P., Paireau J. et al. Estimating the burden of SARS-CoV-2 in France [published online ahead of print, 2020 May 13]. Science. 2020;eabc3517. doi:10.1126/science.abc3517 9) Valenti L., Bergna A., Pelusi S., Facciotti F., Lai A., Tarkowski M. et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. medRxiv 2020.05.11.20098442 doi: http://org/10.1101/2020.05.11.20098442 10) https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forstaresultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19 virus/?fbclid=IwAR0BK_fKQ2l9q4upW4LbMH4celkIaTXIyrvwvOW1RbaoxkJ1DKdEGP Txx6w 11) Sughayer M.A., Mansour A., Al Nuirat A., Souan L., Ghanem M., Siag M. Covid-19 Seroprevalence rate in healthy blood donors from a community under strict lockdown measures medRxiv 2020.06.06.20123919; doi: https://doi.org/10.1101/2020.06.06.20123919 12) Kai Wang-to K., Chi-Chung Cheng V., Cai J. P., Chan K. H., Chen L. L., Wong L. H. at all. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. Lancet microbes, June 2020 DOI: 10.1016/S2666-5247(20)30053-7 13) Filho L.A., Landmann Szwarcwald C., de Oliveira Garcia Mateos S., Monteiro Ponce de Leon A., de Andrade Medronho R., Gonçalves Veloso V et al., Seroprevalence of IgG and IgM anti-SARS-CoV-2 among voluntary blood donors in Rio de Janeiro, Brazil Scielo Electronic Library Online preprint, doi: https://doi.org/10.1590/SciELOPreprints.404 14) Sood N., Simon P., Ebner P., Eichner D., Reynolds J., Bendavid E. et al. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020 [published online ahead of print, 2020 May 18]. JAMA. 2020;e208279. doi:10.1001/jama.2020.8279 15) Ng D., Goldgof G., Shy B., Andrew L., Balcerek J., Bapat S. P. et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. Preprint. medRxiv. 2020;2020.05.19.20107482. Published 2020 May 25. doi:10.1101/2020.05.19.20107482 16) https://www.tuttitalia.it/statistiche/indici-demografici-struttura-popolazione/#:~:text=Struttura%20della%20popolazione%20dal%202002,anziani%2065%2 0anni%20ed%20oltre.

TABLE 1:Detection of antibodies to SARS Cov 2 in 904 healthy blood donors according to sex and age

| | \mathbf{n}° | Positive n° | % |
|---------------------|----------------------|-------------|------|
| Total | 904 | 9 | 0.99 |
| Males | 665 | 5 | 0.75 |
| Females | 239 | 4 | 1.6 |
| | | | |
| Ages (range) | n° | n° | % |
| Group I (18 – 25) | 112 | 1 | 0.89 |
| Group II (26 – 35) | 195 | 4 | 2.0 |
| Group III (36 – 45) | 202 | 1 | 0.49 |
| Group IV (46 – 55) | 246 | 0 | 0 |
| Group IV (56–65) | 149 | 3 | 2.0 |
| | | | |